Comment
Author: Admin | 2025-04-28
Of 0.02 mg/kg every 5–7 days based on therapeutic response and tolerance.SurgeryPreoperatively to Decrease Secretions and Block Cardiac Vagal ReflexesIM0.004 mg/kg given 30–60 minutes prior to the anticipated time of induction of anesthesia or at the time other preanesthetic medications (e.g., opiates, sedatives) are administered.Children 1 month to 2 years of age may require dose of up to 0.009 mg/kg.Intraoperatively to Prevent Cholinergic EffectsIV0.004 mg/kg (maximum 0.1 mg); may repeat as needed at intervals of 2–3 minutes. However, intraoperative doses rarely are needed in children because of long duration of antimuscarinic effects of preoperative dose.Muscarinic Blockade during Anticholinesterase Reversal of Curariform Neuromuscular BlockadeIV0.2 mg for each 1 mg of neostigmine methylsulfate or 5 mg of pyridostigmine bromide.To minimize the appearance of adverse cardiac effects, administer glycopyrrolate simultaneously (e.g., mixed in the same syringe) with the anticholinesterase agent.If bradycardia is present, administer before the anticholinesterase agent to increase pulse to 80 bpm.AdultsCOPDGlycopyrrolateOral Inhalation (Powder)15.6 mcg (contents of one capsule) twice daily.Oral Inhalation (Solution)25 mcg (contents of one single-dose vial) twice daily.Glycopyrrolate/Formoterol Fixed CombinationOral Inhalation (Aerosol)18 mcg of glycopyrrolate and 9.6 mcg of formoterol fumarate (2 inhalations of a preparation containing 9 mcg of glycopyrrolate/4.8 mcg of formoterol fumarate) twice daily.Glycopyrrolate/Indacaterol Fixed Combination:Oral Inhalation (Powder)15.6 mcg of glycopyrrolate and 27.5 mcg of indacaterol (contents of one capsule) twice daily.Peptic Ulcer DiseaseOral (Tablets)Initially, 1 mg 3 times daily (morning, early afternoon, and bedtime); may increase bedtime dose to 2 mg if needed to control overnight symptoms.Alternatively, 2 mg given 2 or 3 times daily at equally spaced intervals.Maintenance dosage of 1 mg twice daily adequate in most adults.Adjust dosage carefully according to individual requirements and response.IV or IM0.1 mg administered at 4-hour intervals 3 or 4 times daily.0.2 mg may be given when a more profound antimuscarinic effect is desired.Some patients may need only a single dose; patient response dictates frequency of administration, up to a maximum of 4 times daily.SurgeryPreoperatively to Decrease Secretions and Block Cardiac Vagal ReflexesIM0.004 mg/kg given 30–60 minutes prior to the anticipated time of induction of anesthesia or at the time other preanesthetic medications (e.g., opiates, sedatives) are administered.Intraoperatively to Prevent Cholinergic EffectsIVUsual dose is 0.1 mg; may repeat as needed at intervals of 2–3 minutes.Muscarinic Blockade during Anticholinesterase Reversal of Curariform Neuromuscular BlockadeIV0.2 mg for each 1 mg of neostigmine methylsulfate or 5 mg of pyridostigmine bromide.To minimize the appearance of adverse cardiac effects, administer glycopyrrolate simultaneously (e.g., mixed in the same syringe) with the anticholinesterase agent.If bradycardia is present, administer before the anticholinesterase agent to increase pulse to 80 bpm.Prescribing LimitsPediatric PatientsDroolingOral (Solution)Maximum 0.1 mg/kg 3 times daily (≤1.5–3 mg per dose based upon weight).AdultsCOPDGlycopyrrolateOral Inhalation (Powder)Maximum 15.6 mcg (contents of one capsule) twice daily.Oral Inhalation
Add Comment